MedPath

EsoCap AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis

Phase 2
Completed
Conditions
Eosinophilic Esophagitis
Interventions
Drug: Placebo
First Posted Date
2021-04-19
Last Posted Date
2023-11-14
Lead Sponsor
EsoCap AG
Target Recruit Count
43
Registration Number
NCT04849390
Locations
🇳🇱

Amsterdam University Medical Center, Amsterdam, Netherlands

🇩🇪

Universitätsklinikum Leipzig AöR, Leipzig, Germany

🇩🇪

Facharztzentrum Eppendorf, Hamburg, Germany

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath